Skip to main content
SpringerLink
Log in

Evaluation of Fecal Myeloperoxidase as a Biomarker of Disease Activity and Severity in Ulcerative Colitis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Subclinical inflammation in ulcerative colitis (UC) can predispose to relapses and biomarkers can detect mucosal inflammation.

Aims

To study the role of fecal myeloperoxidase (FMPO) in assessing disease activity and response to therapy in UC.

Methods

Patients with UC attending our hospital from July 2005 to September 2006 were studied. All patients underwent clinical, endoscopic, and histological assessment for disease extent and severity. Estimation of FMPO levels at baseline and on follow-up was carried out. Age-matched healthy controls were studied for FMPO levels.

Results

A total of 55 patients of UC (30 males, 25 females, mean age 38.6 ± 12 years) and 54 age-matched controls (mean age 37.6 ± 13.6 years) were studied. Cases had higher median MPO levels than controls (0.42 [IQR 0.84] vs. 0.06 [IQR 0.12]); (p < 0.001). Cases with endoscopically more severe disease (Gr III & IV; n = 18) had higher median FMPO levels compared to those with milder disease (Gr II, n = 37), [0.075 (IQR 1.315) vs. 0.315 (IQR 0.813); p = 0.02]. The median MPO level in 27 patients was 0.58 [IQR 0.89] units/ml at presentation which on follow-up decreased significantly to 0.18 [IQR 0.42] units/ml (p value 0.002). However, there was no significant association between FMPO and endoscopic extent and histological scores of activity and chronicity.

Conclusions

Fecal MPO is an effective biomarker for assessing disease activity and response to therapy in patients with ulcerative colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.

    PubMed  CAS  Google Scholar 

  2. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.

    Article  PubMed  CAS  Google Scholar 

  3. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584–5589.

    Article  PubMed  Google Scholar 

  4. Silberer H, Küppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117–126.

    PubMed  CAS  Google Scholar 

  5. Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci. 1997;42:394–403.

    Article  PubMed  CAS  Google Scholar 

  6. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  7. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.

    Article  PubMed  Google Scholar 

  8. Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 2002;97:360–369.

    Article  PubMed  CAS  Google Scholar 

  9. D’Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429–437.

    Article  PubMed  Google Scholar 

  10. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–409.

    Article  PubMed  CAS  Google Scholar 

  11. Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa and cytologic picture of mucosal exudates in ulcerative colitis. Scand J Gastroenterol. 1970;5:625–632.

    Google Scholar 

  12. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383–1389.

    PubMed  CAS  Google Scholar 

  13. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;24(317):1625–1629.

    Article  Google Scholar 

  14. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206–209.

    Article  PubMed  CAS  Google Scholar 

  15. Van der Sluys Veer A, Biemond I, Verspaget HW, Lamers CB. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol. 1999;230:106–110.

    Google Scholar 

  16. Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol. 1994;89:S53–S65.

    PubMed  CAS  Google Scholar 

  17. Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J. 1998;45:69–73.

    Article  PubMed  CAS  Google Scholar 

  18. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344–1350.

    PubMed  CAS  Google Scholar 

  19. Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980;303:27–34.

    Article  PubMed  CAS  Google Scholar 

  20. Sangfelt P, Carlson M, Thörn M, Lööf L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol. 2001;96:1085–1090.

    Article  PubMed  CAS  Google Scholar 

  21. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.

    Article  PubMed  Google Scholar 

  22. Masoodi I, Kochhar R, Dutta U, et al. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol. 2009;24:1768–1774.

    Article  PubMed  CAS  Google Scholar 

  23. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359–367.

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, King Fahad Medical City, Riyadh, Saudi Arabia

    Ibrahim Masoodi

  2. Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160 012, India

    Rakesh Kochhar, Usha Dutta, Chetana Vaishnavi, K. K. Prasad, Shabnum Hussain & Kartar Singh

  3. Department of Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160 012, India

    Kim Vaiphei

Authors
  1. Ibrahim Masoodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rakesh Kochhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Usha Dutta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chetana Vaishnavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. K. Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kim Vaiphei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shabnum Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kartar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rakesh Kochhar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masoodi, I., Kochhar, R., Dutta, U. et al. Evaluation of Fecal Myeloperoxidase as a Biomarker of Disease Activity and Severity in Ulcerative Colitis. Dig Dis Sci 57, 1336–1340 (2012). https://doi.org/10.1007/s10620-012-2027-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2027-5

Keywords

Search

Navigation